





RealRate

PHARMACEUTICAL 2020

Viracta Therapeutics Inc.
Rank 155 of 358



The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 66% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	36,322
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,416
Liabilities, Non-Current	281
Other Assets	915
Other Compr. Net Income	1.0
Other Expenses	514
Other Liabilities	0
Other Net Income	472
Other Revenues	2,073
Property and Equipment	3.0
Research and Development	15,412
Selling, General and Administrative Expense	9,949

Output Variable	Value in 1000 USD
Assets	37,240
Liabilities	9,697
Expenses	25,875
Revenues	2,073
Stockholders Equity	27,543
Net Income	-23,330
Comprehensive Net Income	-23,330
Economic Capital Ratio	102%